炬華科技(300360.SZ):炬華聯昕參股公司正帆科技IPO上會獲通過
格隆匯6月17日丨炬華科技(300360.SZ)公佈,公司於2020年6月16日在上交所網站獲悉,根據上交所科創板股票上市委員會2020年第44次審議會議結果公告,公司產業併購基金炬華聯昕參股的正帆科技提交的首次公開發行股票並在科創板上市的申請獲得審核通過。
正帆科技是一家致力於半導體、光纖通信、醫藥製造等行業客户提供工藝介質和工藝環境綜合解決方案的高新技術企業。其主營業務包括:(1)氣體化學品供應系統的設計、生產、安裝及配套服務;(2)高純特種氣體的生產、銷售;(3)潔淨廠房配套系統的設計、施工。
截至目前,炬華聯昕持有正帆科技234.4666萬股,佔其首次公開發行前總股本的1.22%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.